HITT SHARMA

Employment

• Serum Institute of India Pvt Ltd Medical Director
  2000 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (29)

• A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants
  npj Vaccines 2024 DOI: 10.1038/s41541-024-00828-w
  +Save
• A Phase I study to evaluate safety and tolerability of DTaP-IPV
  Vaccine: X 2023 DOI: 10.1016/J.JVACX.2023.100300
  +Save
• A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults
  Vaccine: X 2023 DOI: 10.1016/J.JVACX.2023.100313
  +Save
• Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial
  The Lancet Oncology 2023 DOI: 10.1016/S1470-2045(23)00480-1
  +Save
• Multiplexed bead-based assay for the simultaneous quantification of human serum IgG antibodies to tetanus, diphtheria, pertussis toxin, filamentous hemagglutinin, and pertactin
  Frontiers in Immunology 2023 DOI: 10.3389/FIMMU.2023.1190404
  +Save
• Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in…
  Vaccine 2023 DOI: 10.1016/J.VACCINE.2023.09.060
  +Save
• Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India
  Expert Review of Vaccines 2023 DOI: 10.1080/14760584.2023.2188942
  +Save
• VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study
  Clinical Infectious Diseases 2023 DOI: 10.1093/CID/CIAC881
  +Save
• A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16-24 months
  Human Vaccines & Immunotherapeutics 2022 DOI: 10.1080/21645515.2022.2146435
  +Save
• Th1-Th2 Seesaw: An Essential Aspect in Type 1 Diabetes
  Current Diabetes Reviews 2022 DOI: 10.2174/1573399818666220308162514
  +Save